anti plod1 antibody (ABclonal Biotechnology)
ABclonal Biotechnology is a verified supplier 
93
Structured Review
ABclonal Biotechnology
anti plod1 antibody
Anti Plod1 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantile-quantile+plot+(qq+plot)/PLOD1+Rabbit+pAb/pm39424162-154-3-6
Average 93 stars, based on 2 article reviews
Anti Plod1 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantile-quantile+plot+(qq+plot)/PLOD1+Rabbit+pAb/pm39424162-154-3-6
Average 93 stars, based on 2 article reviews
anti plod1 antibody - by Bioz Stars,
2026-11
93/100 stars
Images
1) Product Images from "PLOD1 promote proliferation and migration with glycolysis via the Wnt/β-catenin pathway in THCA."
Article Title: PLOD1 promote proliferation and migration with glycolysis via the Wnt/β-catenin pathway in THCA.
Journal: Genomics
doi: 10.1016/j.ygeno.2024.110943
Figure Legend Snippet: Fig. 1. PLOD1 expression was positively correlated with THCA progression. A-C. PLOD1 expression in TCGA-THCA database was analyzed by the Ualcan website. D. The overall survival (OS) rates were determined using GEPIA website. E-G. PLOD1 expression in THCA tissues and its paired adjacent normal tissues was assessed via western blot, qRT-PCR and immunohistochemistry assay. H and I. PLOD1 levels in THCA cells (BHT101, KTC1, TPC1 and CAL-62) and the primary human thyroid follicular epithelial cell line (Nthy-ori 3–1) were tested via qRT-PCR and western blot. *P < 0.05.
Techniques Used: Expressing, Western Blot, Quantitative RT-PCR, Immunohistochemistry
Figure Legend Snippet: Fig. 2. PLOD1 depletion dampened THCA cell proliferation, while enhanced apoptosis. The sequences of si-NC and si-PLOD-1, 2, and 3 were transfected into BHT101 and TPC1 cells, respectively. The vector and pcDNA3.1-PLOD1 was transfected into KTC1 cells. A. Cell transfection efficiency was tested via western blot. B–D. BHT101, TPC1 cell and KTC1 cell viability, colony formation and proliferation were assessed by CCK- 8 assay, colony formation assay and EdU corporation assay, respectively. E. BHT101 and TPC1 cell apoptosis was analyzed via flow cytometry analysis. F. Apoptosis- related proteins (Bcl-2, Bax and cleaved-PARP) expression were assessed by western blot. *P < 0.05, **P < 0.01.
Techniques Used: Transfection, Plasmid Preparation, Western Blot, CCK-8 Assay, Colony Assay, Flow Cytometry, Expressing
Figure Legend Snippet: Fig. 3. PLOD1 depletion impeded THCA cell invasion and migration. The sequences of si-NC and si-PLOD-1 and 3 were transfected into BHT101 and TPC1 cells, respectively. The vector and pcDNA3.1-PLOD1 was transfected into KTC1 cells. A. BHT101, TPC1 and KTC1 cell migration was assessed by wound healing assay. B.EMT-related proteins (E-cadherin, Vimentin and N-cadherin) expression were evaluated by western blot. C and D. BHT101, TPC1 and KTC1 cell migration and invasion were assessed via transwell assay. **P < 0.01.
Techniques Used: Migration, Transfection, Plasmid Preparation, Wound Healing Assay, Expressing, Western Blot, Transwell Assay
Figure Legend Snippet: Fig. 4. PLOD1 might function as an oncogene in THCA via being positively regulated by its transcription factor MAZ. A. The upstream transcription factor of PLOD1 was predicted with the hTFtarget database. The transcription factor positively correlated with PLOD1 that derived from TCGA-THCA was identified by Venn diagram analysis. B. The result of Pearson correlation analysis between PLOD1 and MAZ. C. The targeting relationship between PLOD1 and MAZ was analyzed by dual-luciferase reporter assay. D. The empty vector and recombinant MAZ overexpressing vector were transfected into BHT101 and TPC1 cells, respectively. PLOD1 and MAZ levels were detected by western blot. E and F. BHT101 and TPC1 cell proliferation and apoptosis were tested by colony formation assay and flow cytometry analysis, respectively. G. BHT101 and TPC1 cell migration and invasion were assessed by transwell assay. *P < 0.05.
Techniques Used: Derivative Assay, Luciferase, Reporter Assay, Plasmid Preparation, Recombinant, Transfection, Western Blot, Colony Assay, Flow Cytometry, Migration, Transwell Assay
Figure Legend Snippet: Fig. 5. PLOD1 depletion impeded THCA cell glycolysis. The sequences of si-NC and si-PLOD-1 and 3 were transfected into BHT101 and TPC1 cells, respectively. A and B. GSEA with PLOD1 in TCGA-THCA was carried out with the LinkedOmics webtool. C-E. Glycolysis-related indicators including glucose uptake, lactate production and ATP/ADP ratio were assessed. F. Glycolysis-related proteins expression levels were detected by western blot. *P < 0.05.
Techniques Used: Transfection, Expressing, Western Blot
Figure Legend Snippet: Fig. 6. PLOD1 depletion exerted tumor-impeding roles in THCA via deactivating the Wnt/β-catenin pathway. BHT101 and TPC1 cells were treated with 0.5 μM of BML-284 for 48 h. The sequences of si-NC and si-PLOD-1, 2, and 3 were transfected into BHT101 and TPC1 cells, respectively. A. GSEA was also conducted with the cluster Profiler package in R using the TCGA-THCA database. B. GSEA curve of the Wnt/β-catenin pathway. C. Wnt/β-catenin pathway-related proteins (Cyclin D1, β-catenin, GSK-3β and WNT5A) expression were assessed by western blot. D. The β-catenin expression in the nucleus and cytoplasm was detected by nucleocytoplasmic separation western blot. E. The nuclear localization of β-catenin in BHT101 and TPC1 was detected using immuno fluorescence. F. The TOP/FOP luciferase reporter assay in PLOD1-depleted BHT101 and TPC1 cells. G. Wnt/β-catenin pathway-related proteins (Cyclin D1, β-catenin, GSK-3β and WNT5A) expression were assessed by western blot. H and I. BHT101 and TPC1 cell proliferation and apoptosis were tested by colony formation assay and flow cytometry analysis, respectively. J. BHT101 and TPC1 cell migration and invasion were analyzed by transwell assay. *P < 0.05.
Techniques Used: Transfection, Expressing, Western Blot, Fluorescence, Luciferase, Reporter Assay, Colony Assay, Flow Cytometry, Migration, Transwell Assay
Figure Legend Snippet: Fig. 7. PLOD1 depletion suppressed THCA tumor growth and glycolysis via deactivating the Wnt/β-catenin pathway. The nude mice were divided into the NC group and the PLOD1-depletion group. Each mouse was subcutaneously injected with 100 μl of shRNA-PLOD1 or shRNA-NC transfected TPC1 cells (3.5 × 103 cells/μl) on the dorsal flanks. A-C. The tumor volume and weight of each group were calculated and recorded. D and E. Cell proliferation and apoptosis in the generated tumor were tested by immunohistochemistry assay and TUNEL assay, respectively. F and G. Expression of glycolysis and Wnt/β-catenin pathway-related proteins were tested by western blot. *P < 0.05, **P < 0.01.
Techniques Used: Injection, shRNA, Transfection, Generated, Immunohistochemistry, TUNEL Assay, Expressing, Western Blot
Related Articles
Expressing:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Western Blot:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Quantitative RT-PCR:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Immunohistochemistry:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Transfection:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Plasmid Preparation:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: CCK-8 Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Colony Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Flow Cytometry:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Migration:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Wound Healing Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Transwell Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Derivative Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Luciferase:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Reporter Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Recombinant:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Fluorescence:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Injection:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: shRNA:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Generated:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: TUNEL Assay:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Immunofluorescence:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: FACS:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Knockdown:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: Over Expression:Article Title: PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle Article Snippet: |